Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and JS004 in Second-Line Recurrent/Metastatic ccRCC
NCT06690697Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tifcemalimab in clear cell renal cell carcinoma (ccRCC), sponsored by Fudan University. Started Jun 2024; status: recruiting.
02
Drugs
tifcemalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06690697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690697.